We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
-17.28%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$222M
AUM Growth
-$86.4M
(-28%)
Cap. Flow
-$22.6M
Cap. Flow
% of AUM
-10.18%
Top 10 Holdings %
Top 10 Hldgs %
33.77%
Holding
109
New
40
Increased
8
Reduced
21
Closed
35
Top Buys
| 1 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$11.9M |
| 2 |
Amgen
AMGN
|
+$7.88M |
| 3 |
Gilead Sciences
GILD
|
+$7.77M |
| 4 |
CELG
Celgene Corp
CELG
|
+$7.45M |
| 5 |
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
|
+$6.84M |
Top Sells
| 1 |
Biogen
BIIB
|
+$12.1M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$10M |
| 3 |
ENDP
Endo International plc
ENDP
|
+$9.56M |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$9.04M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$7.41M |
Sector Composition
| 1 | Healthcare | 82.57% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
DELISTED
Allergan plc
AGN
| $10.2M | 4.59% |
37,500
-7,500
| -17% | -$2.3M |
|
|
NUVA
2
DELISTED
NuVasive, Inc.
NUVA
| $8.44M | 3.8% |
175,000
-60,000
| -26% | -$3.1M |
|
|
FPRX
3
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $7.7M | 3.46% |
500,000
+75,000
| +18% | +$1.61M |
|
|
MNK
4
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $7.67M | 3.45% |
+120,000
| New | +$11.9M |
|
|
ZLTQ
5
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| $7.53M | 3.39% |
235,000
+85,000
| +57% | +$2.81M |
|
|
NSTG
6
DELISTED
NanoString Technologies, Inc.
NSTG
| $7.2M | 3.24% |
450,000
+50,000
| +13% | +$783K |
|
|
7
Amgen
AMGN
$198B
| $6.92M | 3.11% |
+50,000
| New | +$7.88M |
|
|
8
Gilead Sciences
GILD
$167B
| $6.87M | 3.09% |
+70,000
| New | +$7.77M |
|
|
CELG
9
DELISTED
Celgene Corp
CELG
| $6.49M | 2.92% |
+60,000
| New | +$7.45M |
|
|
10
CALL
Alnylam Pharmaceuticals
ALNY
$35.7B
| $6.03M | 2.71% |
+75,000
| New | +$8.33M |
|
11
CALL
Bristol-Myers Squibb
BMY
$124B
| $5.92M | 2.66% |
+100,000
| New | +$6.34M |
|
|
AVDL
12
DELISTED
Avadel Pharmaceuticals
AVDL
| $5.71M | 2.57% |
350,000
-225,000
| -39% | -$4.96M |
|
13
Edwards Lifesciences
EW
$49.4B
| $5.69M | 2.56% |
+240,000
| New | +$5.79M |
|
|
HZNP
14
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $5.45M | 2.45% |
275,000
+75,000
| +38% | +$2.37M |
|
15
Community Health Systems
CYH
$465M
| $5.13M | 2.31% |
+145,200
| New | +$6.66M |
|
|
ZGNX
16
DELISTED
Zogenix, Inc.
ZGNX
| $5M | 2.25% |
+370,000
| New | +$6.67M |
|
|
HTWR
17
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
| $4.71M | 2.12% |
+90,000
| New | +$6.84M |
|
18
Integra LifeSciences
IART
$1.5B
| $4.47M | 2.01% |
+150,000
| New | +$4.69M |
|
19
Arcturus Therapeutics
ARCT
$172M
| $4.16M | 1.87% |
98,423
+12,709
| +15% | +$669K |
|
|
GNMK
20
DELISTED
GenMark Diagnostics, Inc
GNMK
| $4.13M | 1.86% |
525,000
-225,000
| -30% | -$2.08M |
|
|
DVAX
21
DELISTED
Dynavax Technologies
DVAX
| $4.05M | 1.82% |
+165,000
| New | +$4.67M |
|
22
HCA Healthcare
HCA
$82.3B
| $3.87M | 1.74% |
+50,000
| New | +$4.43M |
|
|
AEGR
23
DELISTED
Aegerion Pharmaceuticals
AEGR
| $3.4M | 1.53% |
+250,000
| New | +$4.45M |
|
24
Pacira BioSciences
PCRX
$1.01B
| $3.29M | 1.48% |
+80,000
| New | +$4.9M |
|
25
Intuitive Surgical
ISRG
$122B
| $3.22M | 1.45% |
63,000
-117,000
| -65% | -$6.63M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q3 2015 Portfolio in Review
As of Q3 2015, Ghost Tree Capital held 109 positions worth $222M, down 28% from $309M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Ghost Tree Capital withdrew a net $22.6M in Q3 2015, closing 35 positions and reducing 21 holdings. Its most notable exit was Biogen, an estimated $12.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 86% a quarter earlier, followed by Financials.
Against the trend, Ghost Tree Capital opened a new position in MALLINCKRODT PUBLIC LIMITED COMPANY worth $7.67M.
- Ghost Tree Capital's largest Q3 2015 buy was MALLINCKRODT PUBLIC LIMITED COMPANY: 120,000 shares worth $7.67M.
- Ghost Tree Capital added most to ZELTIQ Aesthetics, Inc. in Q3 2015, an estimated $2.81M increase.
- Ghost Tree Capital's biggest Q3 2015 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $7M.
- Ghost Tree Capital fully exited Biogen in Q3 2015, selling an estimated $12.1M.
- Ghost Tree Capital's ten largest holdings make up 34% of its $222M portfolio in Q3 2015.
- Ghost Tree Capital opened 40 new positions and closed 35 in Q3 2015.
- Ghost Tree Capital's portfolio value fell 28% quarter-over-quarter to $222M.
Based on Ghost Tree Capital's 13F filing for Q3 2015, filed 16 Nov 2015.